Information Provided By: 
Fly News Breaks for April 4, 2016
EW
Apr 4, 2016 | 07:50 EDT
Leerink analyst Danielle Antalffy raised her price target for Edwards Lifesciences to $115 from $93, following better-than-expected Sapien 3 data on patients at intermediate risk for open-heart surgery. Antalffy says Sapien 3 was "overwhelmingly superior" to surgery in intermediate risk patients. The analyst continues to model a Q4 approval for Sapien 3, but now assumes that the adoption ramp will occur more quickly than previously expected. Antalffy reiterates an Outperform rating on the shares.
News For EW From the Last 2 Days
There are no results for your query EW
